Alzamend Neuro is trading 6.02% down at $1.29 in pre-market on October 5, alongside secondary coverage reporting AL001 trial dosing. - The October 5 report said dosing began in a Phase 2A study in healthy people, evaluating safety and tolerability; the trial began in May. - The investor-relations page still lists September 16 as its latest release and does not confirm the announcement. - No source explicitly links the announcement to the decline; supplied broader-market moves were modest.